The $100 Club - Were You Early To The Triple-Digit Rally In ABVX, NUTX, BLTE…?

Six primarily biotech and healthcare companies crossed the $100 share-price threshold after clinical and corporate catalysts: ABIVAX (ABVX) hit $100 on Oct. 30, 2025 and is advancing Obefazimod in global phase III ABTECT with planned FDA/EMA filings in H2 2026 (ABVX rose from $7.83 on July 1, 2025 to an intraday high of $138.49; last $113.16). Nutex Health (NUTX) breached $100 on Apr. 9, 2025 on a turnaround with nine-month 2025 revenue of $723.6M and net income of $59.0M versus $222.3M revenue and a $9.5M loss in the first nine months of 2024 (last $166.84). Notable corporate events include Merck’s agreed $221.50-per-share acquisition of Cidara (CDTX) valuing the company at ~ $9.2B (close expected Q1 2026), successful phase 3 results and planned NDA filings at Belite (BLTE), NDA submission for Celcuity’s Gedatolisib, and positive trial readouts at Palvella — signals of sector-specific upside from clinical milestones and M&A activity.

Analysis

Market structure: Late-stage biotech winners (PVLA, BLTE, CELC, ABVX) plus operational healthcare NUTX benefit from compressed risk premia and heightened M&A interest (Cidara buyout by MRK validates bids near $200+). Losers include leveraged short sellers and early-stage peers with no near-term catalysts; pricing power shifts to holders of validated assets as pharma acquirers chase scarce phase‑3/approval-ready drugs. Cross-asset: expect higher implied vols in biotech options, tighter credit spreads for takeover targets, and transient risk‑on flows that can mildly pressure USD and lift equities.

Risk assessment: Primary tail risks are FDA non-approval or negative phase‑3 readouts (Q1–Q2 2026 windows), failed deal closings (CDTX), and payer pricing/reimbursement shocks post‑approval; these would produce 30–70% downside for single‑asset names. Immediate (days) risk is momentum reversal; short term (weeks–months) binary readouts and NDA timelines matter; long term (years) commercial execution, manufacturing scale and single‑asset dependency determine realized value. Hidden dependencies: cash runway and covenant dilution, partner milestones, and enrollment competition across similar indications.

Trade implications: Size selective longs in fundamentally validated names and event hedges—use defined‑risk option structures into readouts/NDA windows (enter 4–10 weeks pre‑event). Consider risk‑arbitrage on CDTX until expected close Q1 2026 (small position, cap at 0.5–1% NAV); paired long small‑cap biotechs (BLTE/PVLA) versus short broad biotech ETF to hedge systemic risk. Trim on +20–30% moves and enforce 20–35% stops on equity positions; buy protection if aggregate biotech exposure >3% NAV.

Contrarian angles: Consensus understates payer/pricing and commercial timeline risk—approval ≠ peak sales; valuation multiple expansion may be overdone for names up >5x YTD (ABVX). Historical parallels (2014–16 biotech run) show sharp mean reversion after clustered binary events; unintended consequence: a single high‑impact negative readout could cascade through small‑cap liquidity, amplifying losses. Maintain event‑by‑event sizing and liquidity buffers.

Key Decisions for Investors

• Establish a tactical 1.5% NAV long in NUTX if price ≤ $170 (current reference $166.84), target +30–50% in 6–12 months on continued revenue/profitability; set stop-loss at -20% and reassess after Q4 2025 earnings.
• Deploy a risk‑arbitrage long position in CDTX up to 0.5–1.0% NAV to capture the $221.50 cash consideration, close position on deal close (expected Q1 2026); liquidate if spread widens to >10% (implied deal risk) or regulatory notices appear.
• Build small event-driven equity + options positions in PVLA, BLTE, CELC (0.75–1.25% NAV each) using 3–6 month call spreads: buy near‑the‑money calls and sell calls 30–50% higher to limit premium; exit or roll after topline/NDA outcomes due Q1–H1 2026, cut losses at -35% on negative readouts.
• Hedge aggregated biotech exposure (>3% NAV) with a 3‑month put spread on IBB sized to cover ~50% of net beta (buy 1x ATM put, sell 1x 25% OTM put) to protect against sectorwide cascade risk during clustered binary events.